Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2017 Sep 23;491(3):747-753. doi: 10.1016/j.bbrc.2017.07.116. Epub 2017 Jul 21.

Key differences between apoC-III regulation and expression in intestine and liver.

Author information

1
Department of Nutritional Sciences, University of Connecticut, 1392 Storrs Rd, Storrs, CT 06269-4017, United States.
2
Department of Nutritional Sciences, University of Connecticut, 1392 Storrs Rd, Storrs, CT 06269-4017, United States. Electronic address: alison.kohan@uconn.edu.

Abstract

ApoC-III is a critical cardiovascular risk factor, and humans expressing null mutations in apoC-III are robustly protected from cardiovascular disease. Because of its critical role in elevating plasma lipids and CVD risk, hepatic apoC-III regulation has been studied at length. Considerably less is known about the factors that regulate intestinal apoC-III. In this work, we use primary murine enteroids, Caco-2 cells, and dietary studies in wild-type mice to show that intestinal apoC-III expression does not change in response to fatty acids, glucose, or insulin administration, in contrast to hepatic apoC-III. Intestinal apoC-III is not sensitive to changes in FoxO1 expression (which is itself very low in the intestine, as is FoxO1 target IGFBP-1), nor is intestinal apoC-III responsive to western diet, a significant contrast to hepatic apoC-III stimulation during western diet. These data strongly suggest that intestinal apoC-III is not a FoxO1 target and support the idea that apoC-III is not regulated coordinately with hepatic apoC-III, and establishes another key aspect of apoC-III that is unique in the intestine from the liver.

KEYWORDS:

Apolipoprotein; Chylomicrons; Dietary fat; Dietary fat absorption; FoxO1; Intestine; Lipoproteins

PMID:
28739253
PMCID:
PMC6069593
DOI:
10.1016/j.bbrc.2017.07.116
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center